Search for: "Glaxo Group Limited" Results 1 - 20 of 49
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
29 Feb 2024, 5:17 pm by Kurt R. Karst
  On April 20, 2023, the PTO issued an ORDER TO SHOW CAUSE to Glaxo Group Limited (“Glaxo”) “based on the apparent ineligibility of U.S. [read post]
19 Nov 2020, 3:18 pm by Lawrence B. Ebert
GSK lost its appeal at the CAFC: Following trial, a jury in the United States District Court for the District of Delaware found that defendants GlaxoSmithKline LLC and Glaxo Group Limited (collectively, “GSK”) infringed U.S. [read post]
3 Aug 2020, 7:02 am by Elizabeth McAuliffe (Bristows)
  It is not enough that some persons actually engage in the art at the material time laboured under a particular prejudice if a substantial number of others did not (Re Glaxo Group Ltd’s Patent [2004] RPC 43). [read post]
13 Aug 2018, 5:16 am by Sara Moran
More from our authors: Mediation: Creating Value in International Intellectual Property Disputes by Théophile Margellos, Sophia Bonne, Gordon Humphreys, Sven Stürmann € The post United Kingdom: Glaxo Group Limited & others v Vectura Limited, Court of Appeal of England and Wales, Civil Division, [2018] EWCA Civ 1496, 28 June 2018 appeared first on Kluwer Patent Blog. [read post]
7 May 2017, 11:00 pm
 In May 2016, Glaxo applied to join Sandoz International, Aeropharm and Hexel as defendants (all proposed defendants are within the Sandoz group). [read post]
13 Nov 2015, 8:02 am by Dennis Crouch
Patent No. 6,284,770) was originally owned by Glaxo as was the primary prior art reference (U.S. [read post]
19 Mar 2015, 4:57 pm by Lawrence B. Ebert
(D.I. 537 at ¶¶ 8, 9)NADH and NADPH have distinct chemical structures, with NADPH containing an additional phosphate group. [read post]
21 Oct 2014, 12:00 am
 In Glenmark Generics (Europe) Limited & others v The Wellcome Foundation Limited & Glaxo Group Ltd, [2013] EWHC 148 (Pat), reported by the IPKat here, Arnold J decided that a combination product for treating malaria was obvious. [read post]
21 Feb 2013, 3:45 pm
 Anyway, spotting a recent decision from the Patents Court, England and Wales, by the name of Glenmark Generics (Europe) Limited & others v The Wellcome Foundation Limited &  and Glaxo Group Ltd [2013] EWHC 148 (Pat), his first thought was that it must have something to do with alcohol. [read post]
25 Nov 2012, 1:00 pm
Condition 5 was at issue in this case, and lucky for the court, Mr Justice Laddie had considered this condition in detail in Glaxo Group & Ors v Dowelhurst Ltd (No 2) [2000] FSR 529. [read post]
3 Jul 2012, 8:53 am by Joe Consumer
Meanwhile, this British company is running around the United States trying to pass laws to limit its liability when its drugs kill or sicken U.S. customers. [read post]
3 Jul 2012, 8:53 am by Joe Consumer
Meanwhile, this British company is running around the United States trying to pass laws to limit its liability when its drugs kill or sicken U.S. customers. [read post]
27 Dec 2011, 10:19 am by John Steele
Apple, 2011 US Dist Lexis 46237 (April 29, 2011), a client and its law firm carefully structured and limited which defendants the firm would target in an IP enforcement campaign, so as to avoid having the firm target a company as to which it had a conflict. [read post]
6 Sep 2011, 1:10 pm by Stephen Jenei
Classen states that this statute, as enacted and intended, and as judicially interpreted, is limited to activities conducted to obtain pre-marketing approval of generic counterparts of patented inventions, before patent expiration. [read post]
22 Aug 2011, 1:43 am
In Glaxo Group Ltd’s Patent [2004] RPC 43 (see also 3.30 and 3.31.1), the Patents Court held that unexpected bonus effects not described in the specification could not form the basis of a valid claim to a selection invention. [read post]